Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta-analysis

International Journal of Urology

Volumn 19, Issue 10, 2012, Pages 914-920

  Liu, Guoyuan ^a   Jiang, Deke ^a   Shen, Suqin ^a   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Meta analysis; Murine double minute 2 SNP309; Polymorphism; Prostate cancer

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ARTICLE; ASIAN; CANCER RISK; CARCINOGENESIS; CAUCASIAN; ETHNICITY; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; HOMOZYGOTE; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PUBLISHING; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SNP309 POLYMORPHISM;

ALLELES; CONFIDENCE INTERVALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HOMOZYGOTE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS;

EID: 84866757763     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03067.x     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur. J. Cancer 2010; 46: 3040-52.
3. Pienta KJ, Esper PS. Is dietary fat a risk factor for prostate cancer? J. Natl. Cancer Inst. 1993; 85: 1538-40.
4. Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 2010; 293: 133-43.
5. Imamoto T, Suzuki H, Utsumi T etal. Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol. 2009; 5: 1005-13.
6. Bai J, Dai J, Yu H, Shen H, Chen F. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J. Toxicol. Environ. Health A 2009; 72: 677-82.
7. Lichtenstein P, Holm NV, Verkasalo PK etal. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 2000; 343: 78-85.
8. Dong JT. Prevalent mutations in prostate cancer. J. Cell. Biochem. 2006; 97: 433-47.
9. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 2003; 13: 49-58.
10. Leite KR, Franco MF, Srougi M etal. Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. 2001; 14: 428-36.
11. Khor LY, Desilvio M, Al-Saleem T etal. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 2005; 104: 962-7.
12. Tovar C, Higgins B, Kolinsky K etal. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol. Cancer 2011; 10: 49-58.
13. Bond GL, Hu W, Bond EE etal. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
14. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 2717-23.
15. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007; 28: 2262-7.
16. Kibel AS, Jin CH, Klim A etal. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008; 68: 1179-86.
17. Stoehr R, Hitzenbichler F, Kneitz B etal. Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br. J. Cancer 2008; 99: 78-82.
18. Hirata H, Hinoda Y, Kikuno N etal. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J. Urol. 2009; 181: 1907-12.
19. Xu B, Xu Z, Cheng G etal. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet. Cytogenet. 2010; 202: 76-81.
20. Mandal RK, Mittal RD. Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population? Urol. Oncol. 2010; DOI:10.1016/j.urolonc.2010.05.006.
21. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959; 22: 719-48.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986; 7: 177-88.
24. Tobias A. Assessing the influence of a single study in the meta- analysis estimate. Stata Tech. Bull. 1999; 47: 15-17.
25. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997; 315: 629-34.
26. Duval S, Tweedie R. A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. J. Am. Stat. Assoc. 2000; 95: 89-98.
27. Sun T, Lee GS, Oh WK etal. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin. Cancer Res. 2010; 16: 5244-51.
28. Jaboin JJ, Hwang M, Perez CA etal. No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urol. Oncol. 2011; 29: 4-9.
29. Wang G, Firoz EF, Rose A etal. MDM2 expression and regulation in prostate cancer racial disparity. Int. J. Clin. Exp. Pathol. 2009; 2: 353-60.
30. Woelfelschneider A, Popanda O, Lilla C etal. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis 2008; 29: 1758-64.
31. Xu B, Mi YY, Min ZC etal. p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urol. Int. 2010; 85: 401-5.
32. Wo X, Han D, Sun H etal. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. J. Genet. Genomics 2011; 38: 341-50.
33. Fang F, Yu XJ, Yu L, Yao L. MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med. Oncol. 2011; 28: 981-85.
34. Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res. Treat. 2010; 120: 211-16.
35. Gui XH, Qiu LX, Zhang HF etal. MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. Eur. J. Cancer 2009; 45: 2023-6.
36. Liu GY, Jiang DK, Shen SQ, Yu L. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis. Arch. Med. Res. 2011; 42: 149-55.
37. Bond GL, Hirshfield KM, Kirchhoff T etal. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006; 66: 5104-10.
38. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. MDM2 SNP309 accelerates colorectal tumour formation in women. J. Med. Genet. 2006; 43: 950-2.
39. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int. J. Cancer 2006; 119: 718-21.
40. Hu W, Feng Z, Ma L etal. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res. 2007; 67: 2757-65.